+31% CAGR Growth to Be Achieved by Biosimilar Market by 2023 – Top Companies Profiled: Pfizer, Roche, Eli Lilly, Bayer, Amgen, Sanofi-Aventis, Johnson & Johnson, Novo Nordisk, Merck
Biosimilars or follow-on-biologics are the "copied" and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Regulations for biosimilars play a vital role in maintaining the viability and balance between original and biosimilars products. Various regulatory authorities such as EMA and FDA actively regulate the biosimilars commercialization and development.
View full press release